Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS

Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS

User Photo
Cancer-News

1 week
75 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Christian Marsolais @Theratech_ #AACR20 NEW DATA SHOW THERATECHNOLOGIES’ SORT1+ TECHNOLOGY IS EFFECTIVE IN MANY TREATMENT-RESISTANT CANCERS

The optimisation of the ability of identified natural cancer agents Science has found many compounds in nature that have the ability to combat cancer. Such compounds, however, are often unstable or need to be taken in amounts that are impractical.

Phytochemicals found in plants, such as curcumin, have shown antiproliferative, antiangiogenic, and apoptotic properties against various cancers such as colorectal, ovarian, and breast cancers. However, these phytochemicals have low bioavailability when administered alone and are easily degraded and poorly absorbed through the gastro-intestinal tract.

The findings of a preclinical analysis, in which curcumin was paired with Theratechnologies' patented peptide (peptide-curcumin conjugate) and administered directly to cancer cells, show that in ovarian, breast, melanoma and colorectal cancer models in vitro, TH1901 has 50 to 100 times greater anti-cancer activity than curcumin alone.

Better efficacy and absence of TH1902 neutropenia are not expressed by estrogen receptors, progesterone receptors or human epidermal growth factor receptor 2 (HER2) in triple-negative breast cancer TNBC, which accounts for approximately 10 to 20 percent of breast cancers. It is more aggressive than other breast cancers and SORT1 receptors have been found to be over-expressed by TNBC.

Preclinical data indicate that in vitro TH1902 contributes to substantially improved efficacy at a lower dose compared to docetaxel alone, in a poster presented at AACR. In the same study, when administered at just one-quarter of the indicated dose of docetaxel, TH1902 also demonstrated comparable efficacy to therapeutic doses of docetaxel. When administered alone, at the one-quarter dose, docetaxel had no effect on care.

Furthermore, TH1902's safety profile was superior to docetaxel, because it did not cause neutropenia even after six cycles of treatment. To induce neutropenia, a single 15mg / kg dose of docetaxel alone was necessary.

The poster is online now at aacr.org
Up Next Autoplay